Patrice Hugo, Ph.D. | May 18, 2016

Genomics enhances Clinical Immuno-oncology Trials

Immuno-oncology is developing at an unprecedented rate, with information integrated into drug development almost simultaneously. Accelerated bench-to-bedside practice brings great opportunity, but challenges emerge in the application of genomics to clinical trials. Download this presentation to learn about test services developed by Q2 Solutions to enable translation of immuno-oncology genomics in clinical trials – and to learn about the future of cancer treatment.

Patrice Hugo, Ph.D., Chief Scientific Officer

Related Services:
Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Read More